A serum microRNA classifier for early detection of hepatocellular carcinoma: A multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study

The Lancet Oncology

Volumn 16, Issue 7, 2015, Pages 804-815

  Lin, Xue Jia ^a   Chong, Yutian ^a   Guo, Zhi Wei ^a   Xie, Chen ^a   Yang, Xiao Jing ^a   Zhang, Qi ^a   Li, Sheng Ping ^a   Xiong, Yujuan ^b   Yuan, Yunfei ^a   Min, Jun ^a   Jia, Wei Hua ^a   Jie, Yusheng ^a   Chen, Min Shan ^a   Chen, Mei Xian ^a   Fang, Jian Hong ^a   Zeng, Chunxian ^a   Zhang, Yaojun ^a   Guo, Rong Ping ^a   Wu, Yuankai ^a   Lin, Guoli ^a   Zheng, Limin ^a   Zhuang, Shi Mei ^a   more..

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; HEPATITIS B SURFACE ANTIGEN; MICRORNA; MICRORNA 133A; MICRORNA 143; MICRORNA 145; MICRORNA 192; MICRORNA 29A; MICRORNA 29C; MICRORNA 505; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ARTICLE; CASE CONTROL STUDY; CHRONIC HEPATITIS B; CLASSIFIER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY CANCER; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SERUM; TUMOR VOLUME; BLOOD; CHINA; CLASSIFICATION; CLINICAL TRIAL; EARLY DIAGNOSIS; HEPATITIS B; LIVER TUMOR; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; REFERENCE VALUE; REPRODUCIBILITY;

ADULT; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHINA; EARLY DETECTION OF CANCER; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MALE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84937520198     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00048-0     Document Type: Article

References (38)

1. Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10. Gut 2013, 62:1667-1668.
2. Kamiyama T, Nakanishi K, Yokoo H, et al. Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. Ann Surg Oncol 2009, 16:1560-1571.
3. Bruix J, Sherman M Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236. Practice Guidelines Committee AAftSoLD.
4. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012, 56:908-943. EASL, EORTCEORTC.
5. Wong GL, Chan HL, Tse YK, et al. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology 2014, 59:986-995.
6. Marrero JA, Lok AS Newer markers for hepatocellular carcinoma. Gastroenterology 2004, 127(suppl 1):S113-S119.
7. Bruix J, Sherman M Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022. American Association for the Study of Liver Diseases.
8. Chen CJ, Lee MH Early diagnosis of hepatocellular carcinoma by multiple microRNAs: validity, efficacy, and cost-effectiveness. J Clin Oncol 2011, 29:4745-4747.
9. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009, 30:37-47.
10. Kosaka N, Iguchi H, Ochiya T Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010, 101:2087-2092.
11. Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010, 70:9798-9807.
12. Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011, 29:4781-4788.
13. Tan Y, Ge G, Pan T, et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One 2014, 9:e107986.
14. Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012, 56:167-175.
15. Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011, 50:136-142.
16. Zhang ZQ, Meng H, Wang N, et al. Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol 2014, 9:135-142.
17. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711.
18. Lok AS, McMahon BJ Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
19. Wylie D, Shelton J, Choudhary A, Adai AT A novel mean-centering method for normalizing microRNA expression from high-throughput RT-qPCR data. BMC Res Notes 2011, 4:555-559.
20. Grimes DA, Schulz KF Compared to what? Finding controls for case-control studies. Lancet 2005, 365:1429-1433.
21. Tusher VG, Tibshirani R, Chu G Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121.
22. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011, 12:77-84.
23. Siddiqui O, Ali MW A comparison of the random-effects pattern mixture model with last-observation-carried-forward (LOCF) analysis in longitudinal clinical trials with dropouts. J Biopharm Stat 1998, 8:545-563.
24. Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010, 28:1660-1665.
25. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
26. Toiyama Y, Takahashi M, Hur K, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 2013, 105:849-859.
27. Shrivastava S, Petrone J, Steele R, Lauer GM, Di Bisceglie AM, Ray RB Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression. Hepatology 2013, 58:863-871.
28. Schultz NA, Dehlendorff C, Jensen BV, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 2014, 311:392-404.
29. Roberts TC, Coenen-Stass AM, Wood MJ Assessment of RT-qPCR normalization strategies for accurate quantification of extracellular microRNAs in murine serum. PLoS One 2014, 9:e89237.
30. Xiong Y, Fang JH, Yun JP, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010, 51:836-845.
31. Braconi C, Kogure T, Valeri N, et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 2011, 30:4750-4756.
32. Bae HJ, Noh JH, Kim JK, et al. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene 2014, 33:2557-2567.
33. Parpart S, Roessler S, Dong F, et al. Modulation of miR-29 expression by alpha-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology 2014, 60:872-883.
34. Zhang X, Liu S, Hu T, Liu S, He Y, Sun S Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology 2009, 50:490-499.
35. Gao P, Wong CC, Tung EK, Lee JM, Wong CM, Ng IO Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol 2011, 54:1177-1184.
36. Yang YM, Lee WH, Lee CG, et al. Galpha gep oncogene deregulation of p53-responsive microRNAs promotes epithelial-mesenchymal transition of hepatocellular carcinoma. Oncogene 2014, published online July 28. 10.1038/onc.2014.218.
37. Cheng Z, Liu F, Wang G, Li Y, Zhang H, Li F miR-133 is a key negative regulator of CDC42-PAK pathway in gastric cancer. Cell Signal 2014, 26:2667-2673.
38. Yamamoto Y, Yoshioka Y, Minoura K, et al. An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer 2011, 10:135-150.